NDAORALCAPSULE, EXTENDED RELEASE
Approved
Sep 1983
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 23h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Librelease is an extended-release oral capsule formulation of chlordiazepoxide, a benzodiazepine approved in 1983. It is used to treat anxiety disorders and alcohol withdrawal symptoms by enhancing GABA-mediated inhibition in the central nervous system. The extended-release formulation provides sustained therapeutic levels with potentially improved compliance compared to immediate-release alternatives.
LOE Approaching
With LOE approaching, commercial teams should expect declining market share and potential workforce consolidation; focus will shift to generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on Librelease offers limited career momentum due to its LOE-approaching lifecycle and zero linked job openings. Career development opportunities are constrained, with roles focused on defending market share and managing generic transition rather than growth initiatives.
Brand ManagerField Sales Representative
Worked on LIBRELEASE at Bausch + Lomb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.